Pentoxifylline vaginal - Prokrea

Drug Profile

Pentoxifylline vaginal - Prokrea

Alternative Names: Pentoxifylline vaginal; PKB-171

Latest Information Update: 17 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PROCREA BioSciences
  • Class Anticoagulants; Antithrombotics; Infertility therapies; Small molecules; Vascular disorder therapies; Vasodilators; Xanthines
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Male infertility

Most Recent Events

  • 17 Apr 2017 Chemical structure information added
  • 23 Mar 2017 Prokrea has patent protection for pentoxifylline vaginal (Prokrea's Website, March 2017)
  • 17 Mar 2017 Phase-II clinical trials in Male infertility in Spain (Vaginal) (EudraCT2016-003993-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top